review
focu
role
virus
caus
asthma
exacerb
articl
briefli
review
current
literatur
support
view
special
focu
human
rhinoviru
rv
main
viru
associ
exacerb
asthma
review
refer
possibl
strategi
treatment
includ
discuss
treatment
specif
antivir
therapi
type
interferon
treatment
rv
review
also
includ
discuss
current
therapi
asthma
glucocorticosteroid
b
agonist
therapi
alon
combin
may
relev
virusinduc
exacerb
asthma
final
potenti
futur
antiinflammatoryimmunomodulatori
therapi
focu
nfkb
inhibit
discuss
r
asthma
exacerb
major
caus
respiratori
viral
infect
continu
problem
respiratori
medicin
worldwid
viral
exacerb
due
either
respiratori
syncyti
virus
rsv
coronavirus
influenza
virus
human
rhinovirus
rv
rv
frequent
caus
agent
vitro
vivo
rv
infect
bronchial
epithelium
upregul
rang
proinflammatori
cytokin
chemokin
adhes
molecul
mucin
growth
factor
thought
contribut
loss
lung
function
lower
airway
inflamm
larg
number
mediat
upregul
sole
part
transcript
factor
nfkb
would
suggest
inhibit
function
transcript
factor
may
allevi
symptom
associ
rvinduc
exacerb
asthma
virusinduc
asthma
bronchial
biopsi
sputum
neutrophil
lymphocyt
infiltr
cell
type
therefor
implic
exacerb
pathogenesi
due
lack
small
anim
model
mani
unclarifi
issu
regard
immunolog
rv
infect
relat
exacerb
asthma
recent
studi
estim
econom
impact
asthma
germani
billion
euro
although
actual
cost
viral
exacerb
known
arguabl
would
contribut
significantli
cost
viral
infect
account
asthma
exacerb
children
adult
uk
one
studi
estim
cost
asthma
exacerb
approxim
higher
per
patient
compar
asthma
patient
experi
exacerb
current
medic
need
patient
suffer
viral
exacerb
asthma
larg
unmet
vaccin
rv
rsv
use
influenza
vaccin
reduc
virusinduc
exacerb
remain
controversi
steroid
far
disappoint
abil
control
symptom
model
experiment
rv
challeng
asthmat
highdos
steroid
remain
partial
effect
control
virusinduc
exacerb
asthma
rang
antivir
antirv
compound
combin
use
therapi
rv
infect
variabl
efficaci
control
rvassoci
ill
review
summaris
current
understand
virusinduc
exacerb
asthma
special
focu
rv
includ
epidemiolog
host
defenc
immunolog
studi
treatment
aim
virusinduc
exacerb
also
discuss
emphasi
better
understand
process
infect
upregul
proinflammatori
mediat
gene
express
may
use
aid
design
novel
therapi
virusinduc
asthma
exacerb
overwhelm
evid
respiratori
virus
associ
acut
exacerb
asthma
account
acut
exacerb
common
respiratori
virus
rv
emerg
frequent
respiratori
virus
rsv
influenza
virus
parainfluenza
virus
coronavirus
adenovirus
newli
describ
metapneumovirus
may
also
associ
exacerb
asthma
children
year
age
rsv
infect
common
caus
signific
morbid
form
wheez
bronchiol
older
children
adult
rsv
still
implic
exacerb
acut
asthma
appear
import
rv
influenza
import
pathogen
winter
epidem
outsid
period
major
contributor
exacerb
asthma
recent
data
suggest
human
metapneumoviru
minor
contribut
virusinduc
exacerb
asthma
rel
frequenc
detect
viru
type
exacerb
children
year
adult
found
previou
studi
summaris
fig
repres
approxim
estim
common
respiratori
virus
identifi
virusinduc
exacerb
asthma
similar
distinct
patholog
mechan
action
persist
asthma
virusinduc
exacerb
asthma
similar
distinct
properti
persist
asthma
respiratori
virusinduc
exacerb
asthma
may
occur
patient
phenotyp
differ
atop
phenotyp
characterist
allergeninduc
asthma
one
present
averag
viral
infect
measur
studi
use
viru
cultur
rtpcr
obviou
differ
allergeninduc
asthma
exacerb
inhal
corticosteroid
effect
treatment
persist
asthma
work
efficaci
asthma
exacerb
evid
similar
mechan
action
suggest
fact
allergen
exposur
viru
infect
may
act
synergist
addit
manner
increas
risk
asthma
exacerb
pollut
nitrogen
dioxid
may
also
increas
risk
virusinduc
exacerb
asthma
interest
differ
asthma
exacerb
persist
asthma
highlight
follow
observ
virusinduc
asthma
exacerb
may
differ
persist
allergeninduc
asthma
neutrophil
appear
play
promin
role
exacerb
eosinophil
predomin
latter
lymphocyt
appear
import
import
neutrophil
lymphocyt
asthma
exacerb
support
sever
studi
atop
asthmat
eosinophil
eosinophil
activ
also
increas
virusinduc
asthma
given
mix
aetiolog
like
common
surpris
much
overlap
pathogenesi
differ
also
exist
way
asthmat
respond
viral
infect
may
affect
outcom
infect
henc
diseas
sever
although
asthmat
incid
viral
infect
normal
increas
sever
durat
lower
airway
symptom
reduct
lung
function
normal
recent
studi
also
report
persist
rv
children
suffer
exacerb
asthma
children
show
rv
persist
sever
exacerb
also
increas
level
rv
replic
also
observ
accompani
lower
level
virusinduc
interferon
ifn
b
express
virusinduc
apoptosi
compar
normal
certain
studi
greater
level
proinflammatori
cytokin
elabor
inflammatori
cell
recruit
observ
peripher
blood
mononuclear
cell
asthmat
cultur
rv
exhibit
lower
level
h
cytokin
ifng
suggest
asthmat
may
defect
h
respons
viral
infect
data
support
two
import
point
firstli
viru
exacerb
asthma
differ
properti
persist
allergeninduc
asthma
secondli
research
still
defin
characterist
viral
exacerb
popul
commun
risk
import
point
must
appreci
prior
discuss
new
treatment
virusinduc
exacerb
asthma
human
rvthe
common
viru
associ
exacerb
asthma
rv
belong
picornavirida
famili
virus
virus
small
rna
genom
approxim
kb
nonenvelop
stabl
environ
least
serotyp
divid
major
minor
group
depend
receptor
specif
rv
major
group
rv
bind
human
minor
group
rv
bind
ldl
receptor
differ
receptor
specif
appear
explain
charg
differ
loop
structur
protein
rv
replic
effici
upper
airway
detect
lower
airway
although
replic
remain
proven
vivo
rv
infect
readili
observ
bronchial
epithelium
vivo
ex
vivo
detect
sampl
lower
airway
upper
airway
rv
well
establish
major
viru
associ
exacerb
asthma
also
chronic
obstruct
pulmonari
diseas
copd
use
virusspecif
rtpcr
viru
cultur
techniqu
epidemiolog
studi
observ
rv
highest
incid
respiratori
virus
exacerb
asthma
adult
year
age
approxim
viral
exacerb
due
rv
infect
present
fig
rv
infect
appear
preval
children
return
school
lead
signific
epidem
increas
hospit
admiss
month
septemb
northern
hemispher
thorough
review
epidemiolog
rv
infect
lower
respiratori
tract
avail
elsewher
due
lack
small
anim
model
mani
aspect
immunolog
host
defenc
rv
infect
remain
unelucid
experiment
natur
infect
vitro
infect
lung
epitheli
cell
use
studi
rvinduc
inflamm
asthma
copd
immunolog
rv
infect
rapidli
expand
field
thoroughli
review
elsewher
review
highlight
main
find
discuss
unresolv
issu
interest
reader
direct
follow
recent
review
inform
rv
upregul
express
rang
proinflammatori
mediat
lung
epithelium
vitro
vivo
includ
chemokin
rant
growth
differenti
factor
gmcsf
also
adhes
molecul
vcam
respiratori
mucin
virusinduc
exacerb
asthma
copd
associ
lower
airway
infect
result
lower
airway
inflammatori
respons
characteris
infiltr
cell
neutrophil
eosinophil
activ
local
macrophag
mast
cell
experiment
natur
infect
human
subject
also
shown
subject
infect
rv
show
increas
level
cytokin
nasal
secret
sputum
one
studi
accumul
inflammatori
cell
molecul
correl
increas
symptom
score
anoth
decreas
lung
function
asthmat
give
support
current
hypothesi
local
inflammatori
reaction
contribut
exacerb
asthmat
therefor
upregul
inflammatori
molecul
cell
prevent
diseas
may
prevent
inhibit
rvinduc
inflammatori
cytokinechemokin
product
therefor
repres
import
therapeut
target
asthma
inflammatori
molecul
induc
respiratori
viru
infect
cell
attract
outlin
fig
strike
observ
proinflammatori
molecul
growth
factor
upregul
rv
far
studi
detail
requir
transcript
factor
nfkb
discuss
nfkb
rel
famili
transcript
factor
crel
implic
express
proinflammatori
gene
review
see
nfkb
sequest
cytoplasm
specif
inhibitor
ikb
phosphoryl
upstream
kinas
ikb
ubiquitin
degrad
proteasom
allow
nfkb
transloc
nucleu
upstream
kinas
respons
relay
signal
includ
nfkb
induc
kinas
nik
ikb
kinas
ikk
axb
recent
identifi
ikki
tank
bind
nucleu
nfkb
bind
variou
cisact
site
within
promot
nfkb
respons
gene
promot
transcript
depict
fig
promot
gmcsf
vcam
contain
nfkb
bind
sequenc
nfkb
requir
express
gene
follow
rv
infect
vitro
also
extend
analysi
shown
nfkb
cisact
sequenc
absolut
requir
rvinduc
promot
activ
gene
bronchial
epitheli
cell
identifi
role
ikkb
use
specif
ikkb
inhibitor
serono
mr
edward
sl
johnston
submit
role
nfkb
signal
rvinduc
gene
express
yet
known
howev
seem
like
implic
promot
contain
nfkb
sequenc
import
gene
express
follow
infect
respiratori
virus
role
nfkb
rvinduc
yet
studi
howev
gene
also
nfkb
site
within
promot
requir
gene
express
variou
system
henc
inhibit
nfkb
transloc
nfkb
signal
repres
potenti
area
therapeut
intervent
one
unresolv
question
rv
biolog
nfkb
signal
initi
viru
infect
dsrna
bind
antivir
protein
kinas
pkr
wide
implic
nfkb
signal
via
interact
ikka
b
phosphoryl
ikb
directli
tolllik
receptor
recent
describ
retino
acid
induc
gene
rig
also
activ
nfkb
respons
viral
infect
dsrna
gern
et
al
demonstr
role
pkr
rvinduc
proinflammatori
mediat
bronchial
epitheli
cell
pkr
would
thu
seem
potenti
therapeut
target
rv
exacerb
asthma
howev
pkr
also
implic
benefici
antivir
host
respons
abil
phosphoryl
eukaryot
initi
pkr
caus
termin
host
protein
synthesi
follow
viral
infect
attempt
limit
viral
replic
pkr
also
involv
type
ifn
respons
henc
possibl
benefici
andor
detriment
affect
pkr
inhibit
rv
exacerb
asthma
remain
open
issu
late
earli
saw
great
interest
antirhinovir
treatment
direct
mainli
control
clinic
cold
compound
interfer
viral
attach
uncoat
bind
picornavir
capsid
protein
first
investig
late
rv
proteas
inhibitor
ruprintrivir
much
later
drug
show
broad
inhibit
rv
infect
vitro
mode
action
treatment
option
discuss
review
shown
fig
viral
capsid
binder
first
use
model
experiment
infect
given
singl
dose
mg
intranas
either
h
prior
challeng
continu
day
respect
postchalleng
clinic
cold
activ
nfkb
ikkabg
complex
altern
ikk
complex
consist
ikki
tank
follow
viral
infect
dsrna
recognist
via
pkr
andor
rigi
cytokin
eg
tnfa
via
nik
ikk
phosphoryl
ikb
lead
degrad
proteasom
free
nfkb
subunit
transloc
nucleu
upregul
nfkb
respons
gene
gmcsf
defin
basi
use
tissu
baselin
rate
plu
develop
one
relev
symptom
sore
throat
sneez
etc
given
h
prior
challeng
day
durat
reduc
incid
cold
mean
total
symptom
score
weight
nasal
secret
compar
control
group
given
placebo
effect
durat
clinic
cold
length
time
spent
exhibit
symptom
studi
contrast
oxazolin
test
show
poor
efficaci
experiment
model
dose
consist
mg
oral
dose
everi
h
day
challeng
occur
studi
day
reduc
paramet
test
compar
placebo
includ
incid
cold
mean
total
symptom
score
viral
titr
one
explan
poor
perform
low
level
drug
recov
saliva
nasal
wash
treatment
patient
concentr
greater
minimum
inhibitori
concentr
mic
test
viru
pirodavir
given
intranas
therapi
mg
also
disappoint
studi
natur
viru
infect
pirodavir
reduc
viral
titr
compar
control
group
treat
placebo
durat
cold
mean
total
symptom
score
reduc
pirodavir
antipicornavir
agent
pleconaril
use
randomis
placebocontrol
phase
ii
clinic
trial
treatment
common
cold
pleconaril
act
prevent
uncoat
picornavirus
includ
serotyp
rv
test
vitro
particip
volunt
commenc
treatment
day
clinic
picornaviru
infect
establish
individu
take
pleconaril
taken
mg
dose
liquid
form
mg
tablet
three
time
daili
show
signific
improv
mean
symptom
score
day
commenc
treatment
decreas
mean
durat
ill
despit
promis
initi
result
pleconaril
yet
test
set
rvinduc
exacerb
asthma
rv
proteas
inhibitor
ruprintrivir
agouron
pharmaceut
inc
also
test
doubleblind
placebocontrol
phase
ii
trial
experiment
challeng
rv
proteas
requir
cleavag
rhinovir
precursor
polyprotein
individu
compon
prior
viral
assembl
furthermor
rv
proteas
requir
gener
rna
polymeras
henc
viral
rna
replic
rv
proteas
also
implic
initi
host
cell
signal
lead
proinflammatori
cytokin
product
ruprintrivir
design
use
solv
xray
crystal
structur
rv
proteas
design
bind
irrevers
rv
activ
site
ruprintrivir
demonstr
broad
antipicornavir
spectrum
vitro
mic
mm
studi
utilis
ruprintrivir
either
two
five
time
day
prophylaxi
h
prior
infect
treatment
five
time
day
h
infect
prophylaxi
ruprintrivir
reduc
mean
total
symptom
score
viral
titr
nasal
secret
incid
frequenc
clinic
cold
assess
number
infect
subject
develop
clinic
cold
therapeut
treatment
ruprintrivir
also
reduc
symptom
score
nasal
secret
viral
titr
ruprintrivir
gener
well
toler
despit
studi
requir
numer
deliveri
via
nasal
spray
studi
provid
evid
treatment
clinic
cold
antirhinovir
therapi
use
howev
potenti
problem
approach
respect
potenti
therapi
virusinduc
asthma
exacerb
exampl
therapi
capsid
bind
molecul
led
develop
escap
mutant
could
also
argu
rv
proteas
inhibitor
viru
bind
uncoat
entri
could
stimulu
cell
signal
event
lead
initi
proinflammatori
mediat
gene
express
futur
therapi
aim
prevent
earli
step
viru
uncoat
entri
support
view
studi
ruprintrivir
prevent
suggest
agent
effect
reduc
mediat
product
despit
high
dose
mm
use
therapi
ruprintrivir
administ
via
nasal
spray
also
argu
deliveri
method
may
effect
treat
lower
airway
virusinduc
asthma
exacerb
believ
trigger
furthermor
dose
regim
must
also
suitabl
children
well
adult
set
asthma
exacerb
perhap
critic
mani
studi
durat
clinic
cold
affect
treatment
pleconaril
treatment
success
reduc
durat
clinic
cold
therapi
although
reduc
symptom
may
necessarili
affect
durat
symptom
therefor
may
improv
rate
gener
practition
consult
hospit
admiss
rate
school
work
absente
infect
individu
virusinduc
exacerb
asthma
sever
version
human
use
clinic
studi
includ
solubl
tremacamra
birr
antibodi
fusion
protein
iga
vitro
solubl
prepar
shown
reduc
titr
larg
rang
major
group
rv
tremacamra
test
randomis
doubleblind
placebocontrol
studi
therapeut
prophylact
intervent
challeng
clinic
studi
tremacamra
shown
promis
therapi
reduc
proport
clinic
cold
follow
experiment
challeng
total
symptom
score
nasal
mucu
weight
significantli
lower
releas
day
postinfect
compar
placebo
tremacamra
also
significantli
reduc
replic
day
postinfect
also
tremacamra
use
control
rvinduc
symptom
given
prior
challeng
challeng
establish
symptom
tremacamra
hold
promis
therapi
clinic
cold
howev
test
context
exacerb
asthma
type
ifn
potent
antivir
mediat
rang
effect
limit
viral
infect
dissemin
type
ifn
includ
numer
ifna
ifnb
newli
identifi
ifnl
type
ifn
act
viral
infect
cell
uninfect
cell
induc
wellord
antivir
programm
involv
upregul
activ
rang
ifn
induc
gene
pkr
phosphoryl
henc
block
translat
also
antivir
rnase
l
mx
protein
ifn
induc
apoptosi
induc
ifn
gene
express
autocrin
paracrin
manner
ifn
also
activ
nk
cell
requir
nk
cell
surviv
may
effect
innat
adapt
immun
review
see
type
ifnsa
b
extens
studi
prevent
clinic
cold
sinc
potenti
attract
wide
interest
culmin
sever
report
earli
use
therapi
experiment
infect
previou
studi
suggest
effect
dose
depend
high
dose
iu
per
day
effect
reduc
rv
infect
ill
lower
dose
iu
effect
reduc
ill
symptom
score
necessarili
affect
incid
cold
despit
effect
model
experiment
rv
infect
high
dose
signific
side
effect
observ
includ
bloodting
mucu
even
mucos
histopatholog
abnorm
studi
sought
examin
efficaci
iu
deliv
three
time
daili
day
via
nasal
spray
drop
challeng
occur
h
later
reduc
viru
shed
drop
potent
effect
deliv
via
drop
also
significantli
reduc
nasal
mucu
weight
neither
treatment
reduc
frequenc
clinic
cold
also
test
prophylact
treatment
natur
viral
infect
one
studi
twice
daili
iu
day
demonstr
less
rvassoci
cold
significantli
differ
placebo
anoth
studi
utilis
either
unit
twice
daili
daili
week
control
subject
given
dosematch
placebo
medic
period
twice
daili
greatli
reduc
number
rvassoci
cold
effect
parainfluenzaassoci
cold
effect
ifn
slowli
lost
treatment
period
frequenc
rvassoci
cold
equal
day
posttreat
dose
exhibit
side
effect
mostli
form
nasal
bloodting
mucu
sever
studi
investig
potenti
ifnb
treatment
clinic
cold
first
studi
intranas
administ
recombin
ifnb
ifnb
ser
involv
dose
iu
day
treatment
show
promis
control
experiment
challeng
studi
involv
rv
challeng
occur
fourth
dose
ifnb
significantli
lower
symptom
score
nasal
secret
viru
releas
compar
placebo
next
studi
ifnb
ser
involv
toler
efficaci
studi
experiment
rv
challeng
volunt
pretreat
either
ifnb
ser
iu
h
infect
continu
day
toler
studi
demonstr
numer
side
effect
particularli
highdos
regim
includ
bloodting
mucu
increas
subepitheli
lymphocyt
infiltr
nasal
biopsi
efficaci
studi
also
report
signific
decreas
nasal
mucu
weight
less
develop
incid
clinic
cold
less
viral
shed
differ
signific
highdos
regim
third
studi
involv
prophylaxi
natur
infect
report
quit
disappoint
result
two
randomis
placebocontrol
trial
utilis
ifnb
ser
given
either
day
week
week
iu
higher
dose
iu
consecut
day
studi
fail
show
signific
reduct
incid
clinic
cold
compar
placebo
also
patient
receiv
cold
number
day
ill
differ
ifnb
ser
treat
group
placebo
studi
provid
use
background
assess
potenti
ifn
therapi
viral
exacerb
asthma
advantag
type
ifn
therapi
antirv
therapi
exacerb
asthma
viral
agent
could
control
specif
rv
therapi
would
treat
virusinduc
exacerb
howev
broadspectrum
therapi
ifn
would
disadvantag
particular
studi
suggest
effect
given
prior
experiment
rv
infect
prophylact
therapi
context
natur
rv
infect
ifnb
less
impress
exhibit
effect
given
prior
experiment
rv
challeng
effect
prophylact
natur
infect
believ
differ
due
differ
antivir
activ
ifnb
similar
antirhinovir
activ
vitro
rel
ineffect
ifnb
thought
due
instabl
nasal
spray
howev
use
drop
ifnb
also
perform
prophylact
studi
natur
rv
infect
deliveri
dose
appear
contenti
issu
studi
effect
ifna
depend
upon
high
enough
dose
prevent
infect
clinic
cold
low
enough
prevent
unwant
side
effect
howev
studi
report
side
effect
even
lower
dose
iu
given
daili
argu
side
effect
would
even
problemat
asthmat
particularli
increas
inflamm
nasal
passag
appear
hallmark
intranas
ifn
therapi
anoth
issu
asthmat
would
effect
deliveri
upper
versu
lower
airway
rv
administ
nasal
spray
definit
found
lower
airway
experiment
infect
current
unknown
whether
intranas
appli
ifn
would
act
high
enough
concentr
lower
airway
altern
could
ifn
deliv
via
oral
inhal
similar
inhal
corticosteroid
therebi
ensur
deliveri
lower
airway
ultim
effect
ifn
therapi
rvinduc
exacerb
asthma
yet
investig
ifn
also
test
conjunct
treatment
nonsteroid
antiinflammatori
agent
approach
base
belief
singl
molecul
therapi
prove
effect
rvassoci
clinic
cold
singl
therapi
block
viral
infect
replic
associ
host
respons
infect
includ
cellular
humor
inflammatori
reaction
studi
aim
treat
clinic
cold
combin
treatment
earli
phase
infect
argument
regim
time
would
effect
control
infect
mani
symptom
associ
host
inflammatori
respons
infect
intranas
use
along
ipratropium
oral
naproxen
model
experiment
rv
infect
treatment
given
h
postinfect
continu
day
treatment
effect
reduc
day
viru
shed
viru
titr
compar
placebo
decreas
nasal
mucu
weight
day
postinfect
intranas
also
studi
oral
chlorpheniramin
ibuprofen
versu
treatment
consist
intranas
placebo
oral
chlorpheniramin
ibuprofen
oral
intranas
placebo
experiment
infect
combin
reduc
total
symptom
score
compar
oral
chlorpheniramin
ibuprofen
achiev
placebo
combin
also
significantli
reduc
nasal
mucu
weight
gener
clinic
cold
also
reduc
viral
titr
compar
group
day
postinfect
effect
treatment
durat
clinic
cold
studi
howev
appear
signific
side
effect
associ
combin
treatment
regim
one
fifth
subject
receiv
combin
complain
bloodting
nasal
mucu
drowsi
nasal
dryness
also
common
group
glucocorticosteroid
gc
mainstay
current
asthma
therapi
steroid
administ
topic
potent
inflammatori
agent
act
help
reduc
proinflammatori
molecul
gene
express
oper
larg
level
pretranscript
review
see
steroid
reduc
inflamm
glucocorticoid
receptor
gr
dna
interact
grtranscript
factor
interact
induc
histon
deacetyl
therefor
reduc
dna
unwind
henc
transcript
inflammatori
gene
final
induc
antiinflammatori
agent
despit
evid
steroid
attenu
rvassoci
inflammatori
respons
vitro
use
steroid
virusinduc
exacerb
asthma
remain
controversi
sever
vivo
studi
report
poor
efficaci
steroid
prevent
inflamm
reduct
lung
function
model
experiment
rv
infect
farr
et
al
examin
potenti
use
prednison
mg
twice
daili
intranas
beclomethason
microgram
twice
day
given
day
prior
challeng
prophylact
treatment
model
experiment
rv
infect
treatment
ceas
day
postchalleng
h
treatment
appear
affect
reduc
nasal
obstruct
nasal
mucu
weight
nasal
kinin
concentr
howev
effect
lost
steroid
treatment
ceas
anoth
studi
also
examin
prednison
mg
given
three
time
daili
day
treatment
commenc
h
prior
rv
infect
steroid
reduc
nasal
kinin
mucu
concentr
littl
effect
symptom
viru
load
higher
steroidtr
group
signific
differ
day
postinfect
data
suggest
advers
effect
steroid
may
suppress
antivir
mediat
requir
natur
defenc
viral
infect
vivo
support
yet
observ
vitro
howev
rel
effect
steroid
type
ifn
defensin
envelop
virus
antivir
compon
remain
larg
unexplor
grunberg
et
al
examin
possibl
benefit
inhal
budesonid
mg
twice
daili
treatment
mild
asthmat
experiment
rv
infect
treatment
commenc
week
prior
challeng
maintain
throughout
studi
period
week
postchalleng
budesonid
improv
lung
function
asthmat
decreas
eosinophil
number
reduc
total
inflammatori
cell
number
lung
author
conclud
steroid
gave
partial
protect
rvassoci
inflamm
asthma
anoth
studi
observ
budesonid
treatment
caus
small
signific
increas
solubl
antagonist
nasal
secret
signific
differ
level
asthmat
treat
budesonid
control
asthmat
treat
placebo
data
support
idea
steroid
may
benefit
rvassoci
exacerb
increas
level
antiinflammatori
mediat
within
airway
rather
direct
effect
proinflammatori
mediat
express
use
gc
treat
virusinduc
wheez
children
year
age
also
care
examin
metaanalysi
compil
data
sever
studi
show
mainten
lowdos
inhal
gc
demonstr
clear
reduct
placebo
proport
hospit
admiss
due
viral
wheez
treatment
affect
prescript
rate
oral
gc
treatment
individu
admit
hospit
sever
studi
report
similar
find
contrast
studi
investig
emerg
room
hospit
admiss
commun
case
viral
infect
autumn
canada
reveal
children
patient
admit
hospit
exacerb
less
like
given
prior
treatment
form
inhal
gc
leukotrien
receptor
antagonist
also
two
clinic
studi
consist
older
children
year
adult
shown
gc
alon
fail
reduc
asthma
exacerb
rate
studi
increas
gc
dose
reduc
rate
asthma
exacerb
current
much
evid
suggest
use
gc
alon
partial
protect
virusinduc
exacerb
asthma
prevent
therapi
improv
data
indirectli
support
idea
exacerb
asthma
may
involv
process
differ
persist
asthma
gc
may
act
concert
therapeut
exampl
longact
b
agonist
laba
combin
therapi
laba
act
via
g
protein
coupl
receptor
activ
adenyl
cyclas
second
messeng
camp
induc
intracellular
signal
event
affect
broad
rang
physiolog
process
alon
combin
gc
smooth
muscl
growth
differenti
inflamm
respons
bacteri
infect
sever
persist
asthma
sever
studi
vitro
vivo
shown
combin
use
gc
laba
advantag
use
gc
alon
term
allevi
inflamm
control
smooth
muscl
remodel
improv
lung
function
consid
abil
laba
enhanc
antiinflammatori
properti
gc
exert
antiinflammatori
effect
vitro
import
question
whether
combin
therapi
laba
gc
reduc
asthma
exacerb
rate
studi
complet
thu
far
suggest
posit
effect
b
agonist
combin
gc
reduc
frequenc
asthma
exacerb
howev
evid
requir
use
gc
way
gener
accept
studi
may
also
mix
aetiolog
exacerb
gener
investig
specif
virusinduc
exacerb
also
unclear
whether
enhanc
effect
produc
b
agonist
studi
due
bronchodil
decreas
inflamm
yet
clinic
studi
use
combin
therapi
model
experiment
natur
rv
infect
asthma
studi
perform
potenti
role
combin
therapi
treatment
rvinduc
asthma
exacerb
remain
open
one
caveat
idea
gener
observ
virusinduc
exacerb
asthma
involv
eosinophil
recruit
neutrophil
activ
cell
inflam
airway
also
activ
local
macrophag
abil
combin
therapi
control
neutrophil
lymphocyticinduc
inflamm
yet
investig
experiment
nfkb
involv
induct
major
proinflammatori
mediat
studi
far
rv
infect
see
section
nfkb
signal
compon
repres
possibl
therapeut
target
murin
model
allerg
asthma
success
nfkb
inhibit
redox
inhibitor
nfkb
decoy
oligodeoxynucleotid
success
reduc
proinflammatori
molecul
express
lung
inflamm
airway
hyperrespons
metacholin
recent
studi
shown
rv
induct
bronchial
epitheli
cell
ikkb
depend
process
sensit
inhibit
serono
intern
select
ikkb
inhibitor
mr
edward
sl
johnston
unpublish
observ
suggest
ikkb
inhibit
may
use
therapeut
option
recent
review
given
thorough
summari
current
rang
select
ikk
inhibitor
avail
includ
organicbas
small
molecul
inhibitor
therefor
discuss
detail
importantli
current
rang
select
ikk
inhibitor
begun
find
way
clinic
trial
show
promis
cellbas
assay
murin
model
diseas
inhibitor
type
yet
test
human
model
experiment
viru
infect
asthma
concern
viru
exacerb
asthma
one
caveat
idea
nfkb
inhibit
protect
antivir
mediat
may
also
induc
nfkb
depend
manner
obviou
exampl
ifnb
mani
system
made
initi
viral
infect
nfkb
depend
manner
clearli
potenti
role
nfkb
express
mediat
benefici
host
respons
infect
need
care
consid
nfkb
intervent
becom
seriou
therapeut
option
discoveri
altern
nfkb
signal
intermedi
ikki
proposit
nfkb
inhibit
becom
complex
see
fig
howev
role
individu
nfkb
signal
intermedi
harm
proinflammatori
mediat
gene
express
well
use
antivir
mediat
gene
express
much
understudi
field
whether
distinct
signal
intermedi
exist
ifn
express
versu
proinflammatori
cytokin
express
current
unclear
research
effort
requir
role
import
transcript
factor
signal
pathway
fulli
understood
mani
respiratori
virus
particular
rv
caus
exacerb
asthma
healthcar
concern
worldwid
rv
upregul
proinflammatori
mediat
caus
local
inflamm
lower
airway
may
precipit
exacerb
asthma
certain
individu
individu
suffer
viral
exacerb
asthma
yet
treat
effect
wide
interest
rang
treatment
option
unmet
medic
need
specif
antirhinovir
therapi
ifn
therapi
steroidbas
therapi
studi
past
mix
success
antivir
therapi
classic
appli
context
clinic
cold
tabl
howev
yet
studi
exacerb
asthma
link
rv
asthma
exacerb
establish
antirhinovir
treatment
pleconaril
tremacamra
regard
seriou
therapeut
option
studi
type
ifn
therapi
clinic
cold
highlight
mani
problem
treatment
dose
deliveri
safeti
remain
import
issu
viral
exacerb
asthma
defici
ifnb
express
recent
describ
asthmat
type
ifn
therapi
remain
candid
treatment
howev
one
potenti
area
research
combin
antivir
antiinflammatori
therapi
may
inhibit
viral
replic
well
treat
upper
lower
airway
inflamm
anoth
area
yet
test
formal
nfkb
inhibit
mani
rvinduc
inflammatori
mediat
nfkb
depend
wealth
literatur
far
report
rvinduc
exacerb
asthma
suggest
relationship
infect
asthma
exacerb
particular
cellular
molecular
immunolog
aspect
pathogenesi
still
unclear
experiment
infect
studi
requir
better
understand
import
process
particular
asthmat
may
differ
normal
individu
suffer
lower
airway
diseas
prioriti
also
need
vigor
pursuit
molecular
mechan
infect
proinflammatori
mediat
induct
exampl
develop
small
anim
model
invalu
test
idea
provid
futur
therapeut
target
refer
symptom
studi
author
refer
success
control
symptom
studi
p
refer
unsuccess
control
particular
symptom
ns
refer
symptom
studi
b
limit
suggest
author
studi
